ExpreS2ion CEO comments ongoing rights issue
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Topp 10: Börsens högst utdelande aktier / Få 3,5 % i sparränta – om du agerar idag

Nyhet

ExpreS2ion CEO comments ongoing rights issue

ExpreS2ion CEO comments ongoing rights issue
Nyhet från Biostock
Publicerad: 05 Apr 2023 08:45
ExpreS2ion Biotech

ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform.

Right now, the company is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine. Meanwhile the cancer vaccine candidate ES2B-C001 is advancing towards the clinic.

The company is currently raising 102 MSEK in a rights issue.

BioStock.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg
Läs hela artikeln hos Biostock

Nyhetsbrev